Teva Pharmaceutical Industries Receives FDA Approval For DEGEVMA To Treat Bone Complications In Patients With Advanced Cancer

Teva Pharmaceutical Industries Ltd. has received FDA approval for DEGEVMA (denosumab-adet), a biosimilar to Xgeva (denosumab), aimed at preventing bone complications in adults with advanced cancer that has metastasized to the bone. This approval, along with the earlier approval of PONLIMSI in March 2026, creates a comprehensive U.S. denosumab biosimilar portfolio, enhancing treatment options for oncology-related bone diseases and osteoporosis care.